Study details
Enrolling now
Alpha Radiation Emitters Device for Pancreatic Cancer Treatment
Alpha Tau Medical LTD.
NCT IDNCT06698458ClinicalTrials.gov data as of Apr 2026
Target enrollment
30
Study length
about 1.5 years
Ages
18–120
Locations
13 sites in AZ, CA, FL +3
What this study is about
This trial is testing a new device, called DaRT, used with chemotherapy to treat pancreatic cancer. The goal is to see if the device is safe when combined with chemotherapy and to assess its effectiveness in treating the cancer.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Use Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Safety -Serious adverse events
Secondary: Complete or pain response
Body systems
Oncology